HBIO (Harvard Bioscience Inc)
Insider Trading Activity
Every open-market purchase and sale reported by HBIO officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-06-12 | Katherine A. Eade | Director | A | — | — |
| 2026-06-11 | Robert E. Gagnon | Director | A | — | — |
| 2026-06-11 | STEPHEN J DENELSKY | Director | A | — | — |
| 2026-06-11 | Seth Benjamin Benson | Director | A | — | — |
| 2026-06-11 | William Snider | Director | A | — | — |
| 2026-04-01 | Mark T Frost | Chief Financial Officer | Buy | — | — |
| 2026-04-01 | Mark T Frost | Chief Financial Officer | A | — | — |
| 2026-03-23 | John D Duke | Chief Executive Officer | A | — | — |
| 2026-03-18 | William Snider | Director | Buy | — | — |
| 2026-03-18 | STEPHEN J DENELSKY | Director | Buy | — | — |
| 2026-03-17 | John D Duke | Chief Executive Officer | Buy | — | — |
| 2025-12-30 | William Snider | Director | A | — | — |
| 2025-10-07 | STEPHEN J DENELSKY | Director | A | — | — |
| 2025-08-19 | James W Green | Director | MIXED | — | — |
| 2025-08-11 | John D Duke | Chief Executive Officer | A | — | — |
| 2025-07-25 | Seth Benjamin Benson | Director | A | — | — |
| 2025-07-18 | Robert E. Gagnon | Director | A | — | — |
| 2025-07-18 | Katherine A. Eade | Director | A | — | — |
| 2025-05-14 | Mark T Frost | Interim CFO | A | — | — |
| 2025-03-21 | Jennifer Cote | Chief Financial Officer | F | — | — |
| 2025-03-21 | James W Green | Chief Executive Officer | F | — | — |
| 2025-01-03 | James W Green | Chief Executive Officer | D | — | — |
| 2024-12-31 | James W Green | Chief Executive Officer | F | — | — |
| 2024-12-31 | Jennifer Cote | Chief Financial Officer | F | — | — |
| 2024-06-14 | James W Green | Chief Executive Officer | Buy | — | — |
| 2024-06-07 | James W Green | Chief Executive Officer | Buy | — | — |
| 2024-05-23 | Thomas W Loewald | Director | A | — | — |
| 2024-05-23 | ALAN I EDRICK | Director | A | — | — |
| 2024-05-23 | Katherine A. Eade | Director | A | — | — |
| 2024-05-23 | BERTRAND LOY | Director | A | — | — |
| 2024-03-07 | James W Green | Chief Executive Officer | A | — | — |
| 2024-03-07 | Jennifer Cote | Chief Financial Officer | MIXED | — | — |
| 2024-01-03 | Jennifer Cote | Chief Financial Officer | F | — | — |
| 2024-01-03 | James W Green | Chief Executive Officer | F | — | — |
| 2023-08-21 | James W Green | Chief Executive Officer | Buy | — | — |
| 2023-06-13 | James W Green | Chief Executive Officer | F | — | — |
| 2023-05-23 | Thomas W Loewald | Director | A | — | — |
| 2023-05-23 | ALAN I EDRICK | Director | A | — | — |
| 2023-05-23 | BERTRAND LOY | Director | A | — | — |
| 2023-05-23 | Katherine A. Eade | Director | A | — | — |
| 2023-03-16 | ALAN I EDRICK | Director | Buy | — | — |
| 2023-03-15 | James W Green | Chief Executive Officer | Buy | — | — |
| 2023-03-08 | Jennifer Cote | Interim CFO | A | — | — |
| 2023-03-08 | James W Green | Chief Executive Officer | A | — | — |
| 2023-01-03 | James W Green | Chief Executive Officer | F | — | — |
| 2023-01-03 | Michael A. Rossi | Chief Financial Officer | F | — | — |
| 2022-12-02 | James W Green | Chief Executive Officer | Buy | — | — |
| 2022-09-15 | BERTRAND LOY | Director | J | — | — |
| 2022-08-29 | BERTRAND LOY | Director | Buy | — | — |
| 2022-08-26 | BERTRAND LOY | Director | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Chief Executive Officer | 406,278 | — |
| — | 10%+ Owner | 375,994 | — |
| — | Chief Executive Officer | 300,515 | — |
| — | 10%+ Owner | 275,726 | — |
| — | Chief Executive Officer | 180,000 | — |
| — | Director | 116,047 | — |
| — | 10%+ Owner | 99,783 | — |
| — | Director | 58,669 | — |
| — | Director | 55,621 | — |
| — | Director | 48,556 | — |
| — | Director | 47,705 | — |
| — | Chief Financial Officer | 47,500 | — |
| — | Chief Operating Officer | 46,972 | — |
| — | Chief Executive Officer | 46,453 | — |
| — | Director | 37,556 | — |
| — | Director | 32,334 | — |
| — | Director | 29,531 | — |
| — | Chief Financial Officer | 27,556 | — |
| — | Director | 27,556 | — |
| — | Director | 27,391 | — |
| — | Chief Financial Officer | 26,358 | — |
| — | VP - Commercial Operations | 24,280 | — |
| — | Chief Financial Officer | 17,161 | — |
| — | Director | 16,494 | — |
| — | Chief Financial Officer | 15,902 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HBIO quote page; the site-wide leaderboard is on the insider transactions hub.